Johnson & Johnson announced that the U.S. FDA has approved TREMFYA for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. This milestone makes TREMFYA the first and only IL-23 inhibitor approved for these pediatric indications and builds on the initial FDA approvals in adults living with moderate to severe plaque PsO in 2017 and active PsA in 2020.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Humana, Vistra, AvePoint, JNJ, Lululemon: Trending by Analysts
- Trump Weekly: President threatens new tariffs, announces TikTok deal
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- Video: Drugmakers, Paccar, Wayfair reacting to Trump tariff threats
- Trump announcement gives big pharma ‘light at end of the tunnel,’ says Jefferies